This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Berd, D. A. Articles by Mitchell, M. S. Search for Related Content PubMed PubMed Citation Articles by Berd, D. A. Articles by Mitchell, M. S.

Immunological Enhancement of Leukemia L1210 by Corynebacterium parvum in Allogeneic Mice¹

Section of Medical Oncology, Departments of Medicine [D. A. B., M. S. M.] and Pharmacology [M. S. M.], Yale University School of Medicine, New Haven, Connecticut 06510

The effect of Corynebacterium parvum on the immune response of C57BL/6 mice (H-2^b) to the allogeneic leukemia L1210 (H-2^d) was investigated. Mice were either left untreated or given C. parvum i.v. or i.p. in various dosages. Seven days later they were challenged with 2.5 to 10 x 10⁶ live L1210 cells i.p. Control animals almost always rejected the challenge. In contrast, most mice pretreated with either 1.0, 0.5, or 0.25 mg of C. parvum i.v. and 1.0 or 0.5 mg i.p. exhibited enhanced growth of leukemia L1210 as indicated by gross ascites and significantly greater weight gain. This sometimes progressed to the death of the animal, but more often regressed after several days. Spleen cell-mediated cytotoxicity to alloantigens, evaluated in vitro by release of ⁵¹Cr from P815Y (H-2^d) target cells, was significantly decreased in the mice pretreated with either 1.0 or 0.5 mg of C. parvum i.v. or 0.5 mg of C. parvum i.p. This suppression could not be reversed by reduction of the concentration of macrophages in the spleen cell suspensions. Complement-dependent cytotoxic antibody, measured by release of ⁵¹Cr from L1210 cells, was profoundly suppressed in mice pretreated with C. parvum i.v. in dosages ranging from 1.0 to 0.1 mg. These data suggest an immunological basis for the enhanced growth of leukemia L1210 caused by C. parvum at these schedules.

¹ Presented in part at the Sixty-Sixth Annual Meeting of the American Association for Cancer Research, May 8, 1975, San Diego, Calif. (2). Supported by USPHS Grant CA-13105 and American Cancer Society Grant IM 50A (Laurens Hammond Memorial Grant for Cancer Research).

² Formerly USPHS Postdoctoral Trainee under Grants CA-05138 and CA-02145. Present address: The Institute for Cancer Research, Philadelphia, Pa. 19111. To whom requests for reprints should be addressed.

³ Research Career Development Awardee, 5KO4-CA-70,982, from the National Cancer Institute, NIH.

Received 10/ 9/75. Accepted 8/ 9/76.